Hepatocellular carcinoma on cirrhosis complicated with tumoral thrombi extended to the right atrium: Results in three cases treated with major hepatectomy and thrombectomy under hypothermic cardiocirculatory arrest and literature review by Pesi, Benedetta et al.
RESEARCH Open Access
Hepatocellular carcinoma on cirrhosis
complicated with tumoral thrombi
extended to the right atrium: results in
three cases treated with major
hepatectomy and thrombectomy under
hypothermic cardiocirculatory arrest and
literature review
Benedetta Pesi1, Francesco Giudici1, Luca Moraldi1, Gianfranco Montesi2, Stefano Romagnoli3, Fulvio Pinelli3,
Pierluigi Stefano2 and Giacomo Batignani1,4*
Abstract
Background: Hepatocellular carcinoma (HCC) with the presence of tumor thrombus in hepatic veins and vena
cava, until the atrium (RATT), is correlated with poor prognosis and with risk of tricuspid valve occlusion, congestive
heart failure, and pulmonary embolism.
Methods: Three patients with HCC on cirrhotic liver with RATT were studied. Operative technique, pre-operative
and post-operative liver function tests, blood loss and transfusions, post-operative morbidity and mortality, and the
overall survival and the disease free survival were analyzed.
Results: Mean operative time was 336 ± 66 min. Intra-operative blood loss was 926.6 ± 325.9 ml. No major
complications occurred. The times of hospital stay were 10, 21, and 19 days, respectively. The survival times were
90, 161, and 40 days, and the disease-free survival times were 30, 141, and 30 days, respectively.
Conclusions: The complete removal of HCC with RATT may be achieved with cardiopulmonary by-pass (CPB) and
total hepatic vascular exclusion (THVE). Adding the hypothermic cardiocirculatory arrest (HCCA) to the use of CPB
allowed us to have minimal blood loss and hemostasis of the resectional plane. So the use of CPB and HCCA
should be considered a good therapeutic alternative to the normothermic CPB with THVE.
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Background
Hepatocellular carcinoma (HCC) is the third most com-
mon cause of cancer death worldwide [1]. HCC is a pe-
culiar tumor that has a tendency to infiltrate the
vascular structures, and this characteristic, when
present, has been reported as one of the most important
prognostic factors for HCC [2]. Vascular infiltration oc-
curs especially in the veins like the portal branches and
more rarely the hepatic veins. This process may be com-
plicated with the development of macroscopic tumoral
thrombi with possible extension to either the portal vein
trunk or the inferior vena cava/right atrium. Liver trans-
plantation, liver resection, radiofrequency ablation
(RFA), and transcatheter arterial chemoembolization
(TACE) are all possible modalities to treat uncompli-
cated HCC, but three of them such as liver transplant-
ation is contraindicated in the presence of macroscopic
vein tumoral thrombosis while TACE and RFA have no
effects on the thrombus; thus, liver resection with
thrombectomy remains the only possibility to cure these
patients even if there is still much of debate because of
the high rate of hepatic and systemic recurrence [3].
It is well known that the presence of tumor thrombus
in the hepatic veins and vena cava, with an extension up
to the atrium (RATT), is correlated with poor prognosis,
and the survival of patients left untreated may range
from only 3 days to 2 months [4] due to tricuspid valve
occlusion (ball valve syndrome), congestive heart failure,
or pulmonary embolism. Liver resection with cavo-atrial
thrombectomy seem to remain, however, in this urgent
situation, the only effective therapeutic option with re-
ported survival time ranging from 5 to 56 months [5].
While the complete removal of a liver tumor along
with its neoplastic thrombus reaching the vena cava may
be achieved with a total vascular exclusion of the liver,
when it further grows and reaches the right cardiac
chambers, the use of a cardiopulmonary bypass (CPB)
became advisable [6, 7] even if not always mandatory
[8]. Each of these reported techniques has pros and cons
that may be summarized as increased blood loss, incom-
plete thrombus removal, and ischemic organ damage.
Adding the hypothermic cardiocirculatory arrest
(HCCA) to the use of CPB has been reported as safe for
several retroperitoneal malignancies with the advantages
of a reduced blood loss and better and thorough
thrombus removal with lesser ischemic damage [9].
Major concerns and drawbacks of this technique how-
ever are represented by the presence of a preoperative
liver impairment and by the duration and the deepness
of the HCCA. In 2000, Wu et al. have reported the first
case of hepatectomy with RATT removal using HCCA
in a cirrhotic liver [10], and since then, we have not
assisted to other reports, except our first patient in 2010,
that showed very good postoperative outcome [11].
The aim of this study is to report the intra- and post-
operative results and outcomes of three cases of HCC
with RATT surgically treated with the use of CPB and
HCCA, which represents at present, to the best of our
knowledge, the largest series worldwide.
Methods
All patients underwent preoperatively to a selective
transcatheter arterial chemoembolization (TACE) of the
main mass and then a week later by a left and a right
portal embolization performed respectively in the second
and third patient to stimulate the growth of the future
remnant liver. Instead, in the first patient, given the
presence of a complete thrombosis of the left portal
vein, the portal embolization was not performed.
All patients were staged as child A according to the
Child-Pugh classification and liver function evaluated
with conventional liver function tests and with indocya-
nine green hepatic clearance test (ICG test) in order to
assess the quantity of parenchyma to be removed ac-
cording to Makuuchi flow chart [12].
All patients had a chest X-ray, ultrasonography (US) of
the abdomen, and contrast computed tomography (CT)
or magnetic resonance imaging (MRI) of the chest and
abdomen.
Anesthesia
All the described patients received the same anesthesia
standardized as follows. Atropine 0.5 mg IM and diaze-
pam 5 mg per OS were administered as premedication
30 min before surgery. After monitoring (electrocardio-
gram, invasive arterial pressure, SpO2), the induction of
the anesthesia was achieved with sufentanil 0.5–1 mcg/
kg and midazolam 0.1 mg/kg and maintained with pro-
pofol 2.5–4 mg/kg/h and remifentanil 0.2–0.4 mcg/kg/
min at the discretion of the attending anesthesiologist.
Muscle relaxation was achieved with rocuronium
0.6 mg/kg before tracheal intubation, while during sur-
gery, it was administered by continuous infusion at the
dose of 0.3 mcg/kg/min. The lungs were ventilated with
50 % oxygen in air using a semi-open circle system.
Tidal volume was set at 8 ml/kg (ideal body weight), and
ventilatory rate was adjusted to keep the arterial carbon
dioxide partial pressure between 35 and 40 mm Hg. A
positive-end expiratory pressure (PEEP) of 5 cmH2O
was applied until CPB started and ventilation inter-
rupted. After anesthesia induction, a three-lumen central
venous catheter was placed into the internal jugular vein
(echo-guided procedure) for drug administration and
central venous pressure monitoring. Body temperature
was measured with rectal and nasopharyngeal probes.
Before the initiation of CPB, the patients received por-
cine heparin at an initial dose of 300 U/kg, injected IV
before cannulation of the aorta. An additional dose of
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5000 U of heparin was administered when the kaolin ac-
tivated clotting time (ACT) was <400 s, while an add-
itional dose of 2500 U was given if the ACT declined
below 300 s. CPB pump flow was maintained at 2.4 l/
min/m2, and mean arterial pressure (MAP) target was
70 mmHg. Norepinephrine was administered at continu-
ous infusion to increase MAP up to the target.
Hemodynamic monitoring was arterial pressure and
transesophageal echocardiography (TEE)-based until
CPB starts. After CPB initiation, the ventilator was
stopped and the body temperature was lowered, by
means of the heat exchanger, up to 24, 25, and 28 °C in
the first, second, and third patient, respectively. After
the target temperature was reached, 30 mg/kg of methyl-
prednisolone, 250 mg of thyopentone, and 250 ml of
18 % mannitol solution were administered, and 10 min
later, the pump flow was stopped for the surgical pro-
cedure (hypothermic circulatory arrest). At the end of
the surgical procedure, the patients were re-warmed to
37 °C, resuming a spontaneous heartbeat without the
need of defibrillation. The TEE was used as the weaning
phase of the patient from the artificial circulation. After
complete weaning from CPB, heparin was neutralized by
IV infusion of protamine hydrochloride at the dose of
0.6–1 mg per 100 U of heparin administered. Heparin
neutralization was considered adequate if post-
protamine ACT value was within 10 % of the pre-
heparin value. All patients received fresh frozen plasma
at the dose of 10–15 ml/Kg. The presented cases pre-
ceded the acquisition of a rotational thromboelastometry
(ROTEM) device, now used for point-of-care coagulation
monitoring and management. The hematocrit target was
25 % but no patients received packed red blood cells
during surgery. After the procedure, all the patients were
admitted in intensive care unit (ICU) under sedation
with propofol (1 mg/kg/h) and remifentanil (0.1 mcg/kg/
min) until complete re-warming, hemodynamic
stabilization, and exclusion of abnormal bleeding. All the
patients were extubated within 5 h from the end of the
intervention. One patient received four units of red
blood cells for excessive post-operative bleeding without
requiring surgical re-exploration.
Surgical procedure
At operation, the patient was placed in supine position
and the abdomen explored through a bilateral sub-costal
incision with xiphoid extension. I.O. ultrasound was ac-
complished in all cases to rule out the presence of
contralateral liver tumors or metastases and to better
define the liver anatomy and the relationships between
the tumor and the vascular-biliary structures. Liver re-
section was carried out first, tying and cutting the arter-
ial and portal branch, and the bile duct of the hemi-liver
was removed and then parenchymal transection was
performed using a Kelly crush technique under intermit-
tent Pringle maneuver lasting 10 min with 5 min of de-
clamping. In the patient who had a complete thrombosis
of the left portal vein with an extension into the right
branch, a thrombectomy was performed, clamping the
main trunk of the portal vein, opening the confluence,
and extracting it from the right branch, using forceps
and a Fogarty catheter. Liver resection was extended to
the anterior wall of the vena cava, leaving the liver at-
tached at the hepatic vein containing the tumor
thrombus.
The xiphoid incision was extended up to the jugulum
and a median sternotomy performed. The pericardial sac
was opened and, after systemic heparinization, the can-
nulation of the ascending aorta and of the right atrium
with a “vent” in the right superior pulmonary vein was
accomplished in order to perform an extracorporeal cir-
culation with CPB. Then, the CPB was started and the
body temperature lowered by systemic cooling and sa-
line solution iced “slashed” that was placed in the peri-
cardium and around the remnant liver in order to
protect more these organs. There was no additional
brain protection during HCCA. After HCCA had
started, the right atrium and the vena cava were opened
longitudinally and the thrombus removed. After the
closure of the atrium and vena cava by means of 4/0
prolene continuous running suture, the patient was re-
warmed and weaned from the CPB. HCCA median time
was 14 min (range 12–24).
In the two cases of HCC of the left hemi-liver in
whom the thrombus intersected the confluence of the
left and middle hepatic veins (HVs), two different ways
were undertaken. In one case, the middle HV was pre-
served by suturing the outlet of the left HV in the mid-
dle HV, once the thrombus had been removed. In the
other case, the confluence was resected (Fig. 1) and dur-
ing the re-warming phase, we reconstructed the continu-
ity of the middle hepatic vein by means of an
interposition of PTFE ringed graft of 8-mm diameter
anastomosed to the inferior vena cava.
Pathology of the specimen showed a multifocal moder-
ately differentiated hepatocellular carcinoma and focal
clear cell with vascular invasion on cirrhosis.
Results
Three patients, two males and one female with ages 51,
73, and 76 years, had a primary liver tumor (HCC) with
a thrombus extending to the supra-hepatic vena cava
and to the right atrium. The tumor diameters were 6.5,
4.5, and 14 cm, respectively. Two patients had a tumor
in the left hemi-liver, with a thrombus invading the left-
middle HV and extending through the supra-hepatic
vena cava to the right atrium. The first of these two pa-
tients had also an invasion of the left portal vein with an
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extension into the right branch while the second had a
segmental neoplastic pulmonary embolism of the left
pulmonary artery. The third patient has had two tumors
of the right hemi-liver with invasion of the right HV and
extension to the right atrium.
The pre-operative liver function tests are shown in
Table 1.
Mean operative time was 336 ± 66 min. Intra-operative
blood loss was 926.6 ± 325.9 ml. No patients required
intra-operative blood transfusions and only one patient
received four units of blood post-operatively for a
hemoglobin (Hb) level dropped to 7.8 g/dl without signs
of active bleeding and no drainage output.
All liver function tests returned to normal within
1 month of the operation. The postoperative liver func-
tion tests are shown in Fig. 2. The patients had unevent-
ful recovery except for one patient who had right pleural
effusion and abdominal ascites that had to be drained
and treated with medical therapy as diuretics and albu-
min. The times of hospital stay were 10, 21, and 19 days,
respectively. The survival times were 90, 161, and
40 days, and the disease-free survival times were 30, 141,
and 30 days, respectively.
Discussion
HCC tends to invade the intra-hepatic vasculature, espe-
cially the portal vein [13]. The tumor thrombosis of the
hepatic veins and vena cava up to the right atrium is un-
common, with a percentage of incidence reported of
2.9 % by imaging techniques, 0.7 % at operation, and
18.2 % at autopsy in Japan [14]. The therapeutic options
at this stage are few and debatable [3]; however, Lin et
al. [4] reported a median survival of few days in the un-
treated patients. The presence of macroscopic tumoral
thrombosis contraindicates liver transplantation. The
role of TACE in patients with HCC and caval/atrial
thrombosis has been recently investigated by Wang et al.
in 2012 who reported no difference in median survival
time between patients who underwent TACE and those
who did not received any treatment. Furthermore, the
same authors reported a great and significative advan-
tage of a third group with caval/atrial thrombosis, surgi-
cally treated, which showed a survival of 68, 22, and
13 % at 1, 3, and 5 years even if there were only 3 of the
25 patients in whom the thrombus had reached the right
atrium [6].
RATT has major complications as “ball valve syn-
drome” [15], acute pulmonary embolism [16], or con-
gestive heart failure, situations that represent an
impending life-threatening condition that should be sur-
gically treated as soon as possible and being the liver re-
section with thrombectomy, the only therapeutic option
in this setting [10].
From an oncological point of view, however, there still
much of debate about the high recurrence rate and the
real gain in terms of life expectancy in these surgically
treated patients. Anyhow, a review of 18 cases operated
in Japan resulted a mean survival of 11 months with
three patients alive for more than 3 years [17]. These
data were confirmed by two further studies which
showed a mean survival of 11 and 19 months [6, 7] with
three patients alive for more than 5 years and with the
longest survivor of 105 months [6].
From a technical point of view, the RATT can be re-
moved in three different ways. The first is to perform a
total hepatic vascular exclusion (THVE) of the liver
without the use of the CPB [18, 19] but this technique is
indicated for thrombi initially abutting the right atrium
that can be reduced manually or lowering the liver and
the thrombus in the IVC clamping it thereafter above
the thrombus [18] but with the risk of an incomplete re-
section [20]. The second possibility, more largely used
and reported, is to use a normothermic CPB coupled
usually with THVE [5–7, 14, 16, 17, 21–24].
Fig. 1 Intraoperative view of the resected liver during hypothermic
cardiocirculatory arrest. Please note the complete bloodless field
with the transected middle hepatic vein (A, B) after the tumoral
thrombus removal from the atriotomy site (C) already sutured
Table 1 Pre-operative liver function tests
PT (%) Albumin serum (g/dL) Bilirubin serum (g/dL) SGOT (U/L) Indocyanin green retention test (%) Alfa-fetoprotein (ng/dL)
Patient 1 76 4.1 1.8 53 22.3 8.6
Patient 2 74 3.6 1.1 60 23.5 12.4
Patient 3 83 5.1 1.09 76 19 21.5
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The use of extracorporeal circulation with HCCA in
cirrhotic patients has been limited for many years be-
cause of the fear of intra-operative bleeding, possible
brain damage, and post-operative liver failure that might
result in a poor outcome.
Historically in 1981, Ein et al. [25] used HCCA to re-
move RATT from hepatoblastoma in a young child with
normal liver parenchyma. This was the first time that
CPB with HCCA was used in liver surgery and was
followed by Wu et al. who used it to remove an RATT
along with a wedge liver resection of a recurrent HCC
on a cirrhotic liver [10]. Indeed, these authors added the
use of a deep HCCA (18 °C) to the CPB, as a rescue for
massive bleeding due to the dense adhesions around the
liver hilum, that rendered impossible to perform a
THVE and to resect the liver parenchyma first, which is
advisable before the systemic heparinization, and for
these reasons, they complained of 7 l of blood loss.
Ohwada et al. [26] used CPB with mild hypothermia at
29 °C for the successful “en bloc” resection of a HCC in
a cirrhotic liver with a RATT but these authors used the
THVE instead of a proper HCCA. In 2009, we described
our first case of HCC on a diseased liver with tumoral
thrombus extension in the hepatic vein and vena cava
which reached the right atrium treated with an extended
left hepatectomy and tumoral thrombus removal using a
CPB with mild HCCA at 24 °C [11]. Since then, there
were no other cases reported in literature of major hepa-
tectomy with RATT removal with CPB and HCCA on a
diseased liver and then we think that even if our series is
small with only three patients, it could be of unique
interest.
All our three patients belonged to the child class A
and underwent to the assessment of the liver function
by means of indocyanine green retention test to demon-
strate the presence of a good functional reserve [27] but
percentages less than or equal to 25 % were deemed ac-
ceptable because of the presence of the thrombosis of a
one or two hepatic vein/s which had already negatively
affected the liver functionality. However and moreover,
we preferred to add a selective TACE of the main mass
and a portal embolization, of the hemi-liver which had
Fig. 2 Postoperative liver function tests
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to be removed, except in the case where the left portal
branch was already closed by a tumoral thrombus. We
think in fact that adding a sequential arterial and portal
embolization of a hemi-liver could lessen the possibil-
ities of post-operative liver failure when a major resec-
tion is planned [9].
Our surgical strategy entails the liver resection first,
using an intermittent Pringle maneuver, before going on
CPB and HCCA according to other authors [6, 14]. This
has allowed us to have minimal blood loss through a
thorough hemostasis of the resectional plane before hep-
arin administration, and surprisingly enough, we did not
notice any bleeding during the re-warming phase and
after the heparin neutralization. In fact, we have had in
all our patients a blood loss comparable to that of major
hepatectomies with only one patient who received only
four units of blood postoperatively. This appeared quite
different from the data reported in a review from Japan
where the total blood loss ranged from 3 to 14 l [22]
and later by Wakayama et al. in a single institution series
where a median of 6 l with range from 1 to 35 l was
complained in six patients with RATT operated using
CPB with THVE [7]. We have preferred to use a mild
hypothermia at 24 to 28 °C instead of a deep one, at 18 °
C used by Wu et al. [10], because the time necessary to
remove the atrial thrombus along with the liver was ex-
pected to be within 30 min and this may have contrib-
uted to a better maintenance of the hemostasis.
Furthermore, there are increasing data supporting the
less negative effects of the hypothermic versus the nor-
mothermic liver ischemia determined when THVE is
used [28, 29]. We have had a median HCCA time of
only 14 min during which the thrombi were thoroughly
removed, in a complete bloodless field, from the right
cardiac chambers and in one occasion from its propaga-
tion into a phrenic vein as well as, in another patient, to
remove an embolus in the left pulmonary artery. This
supports the fact that HCCA may be superior to the
other techniques in order to obtain a better cleaning of
the tumoral material as previously reported in kidney
surgery [9].
Despite the fact that there is a lot of concern about
the high operative risk, recently, Wang et al. [6] demon-
strated that the liver resection with caval/atrial tumor
thrombectomy can be done with little morbidity and no
mortality using CPB and THVE. Accordingly, we also
did not experience any postoperative death, and major
postoperative complications have been negligible, except
in one patient who showed a prolonged output of ascites
from the drainages, medically treated with albumin and
diuretics infusion, which resolved in few days, in our pa-
tients using HCCA. So we think that this surgical tech-
nique, with a short lasting mild hypothermic circulatory
arrest, should be considered for the removal of atrial
thrombi also in the presence of a well-compensated liver
cirrhosis.
Conclusions
In conclusion, the type of surgical approach is not still
standardized in HCC with tumor thrombosis involving
the hepatic and caval vein up to the heart, but we think
that a combined thoracic and abdominal surgery with
the use of CPB and HCCA should be considered a good
therapeutic alternative to the normothermic CPB with
THVE in the presence of a well-compensated liver cir-
rhosis. HCCA in fact seems to be superior to THVE in
order to reduce the amount of blood loss and to obtain
a better and thorough cleaning from the tumoral
thrombus. Furthermore, the sequential arterial and por-
tal embolization should be performed to stimulate the
liver growth and to improve the liver function in order
to obtain low postoperative complications.
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